Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 4,721 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Signs and Symptoms, Respiratory Clear all

Conditions: Chronic Pain
Interventions: RAVANS; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Pulmonary Arterial Hypertension, Frailty
Interventions: Low-Resistance Training; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
Interventions: TH-4000 (Tarloxotinib); Drug
Lead sponsor: Rain Oncology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more

Conditions: Ventilator Associated Pneumonia
Interventions: Common canister; Other
Lead sponsor: Barnes-Jewish Hospital; Other
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Small Cell Lung Cancer
Interventions: Docetaxel, Oxaliplatin, Bevacizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypoxia
Interventions: Diagnostic test of SPO2; Device
Lead sponsor: ChroniSense Medical Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: COPD
Interventions: Testosterone Enanthate, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions: fostamatinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aspirin-exacerbated Respiratory Disease, Nasal Polyp
Interventions: microRNA; Genetic
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Respiration
Interventions: RSpot Non-Contact Respiratory Rate Spot Check; Device
Lead sponsor: Kai Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
Interventions: 68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography, High Resolution Computed Tomography; Drug · Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Binge Drinking
Interventions: Resonance breathing, Low demand cognitive task; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions: filgrastim, docetaxel, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Non Small Cell Lung Cancer, Metastasis, Recurrence
Interventions: Pembrolizumab, Idelalisib; Drug
Lead sponsor: Asha Nayak; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Obesity
Interventions: High-resistance inspiratory muscle strength training, Very-low-resistance inspiratory muscle strength training; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Frailty
Interventions: High Intensity Walking; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 60 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab, Cetuximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Ann Arbor, Michigan + 1 more

Conditions: Altered Mental Status, Sepsis, Heart Failure, Hemorrhage, Respiratory Distress Syndrome, Adult, Cardiac Arrest
Interventions: 731 Series Ventilator; Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 5
States / cities: Hartford, Connecticut • Baton Rouge, Louisiana • Uxbridge, Massachusetts + 2 more

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Refractory Chronic Cough
Interventions: Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG, Amitriptyline 50 MG, Placebo 30 MG, Placebo 60 MG; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Snoring, Sleep Disturbances, Hypoxia, Obstructive Sleep Apnea (OSA)
Interventions: Not listed
Lead sponsor: Case Western Reserve University; Other
Eligibility: 20 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Low Back Pain
Interventions: Naproxen, Omeprazole, Placebo; Drug
Lead sponsor: Apkar Apkarian; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions: Pazopanib, Placebo oral capsule; Drug
Lead sponsor: Cure HHT; Other
Eligibility: 18 Years to 85 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more

Search by objective public record fields.

Respiratory-Gated Vagal Nerve Stimulation for Chronic Pain

Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Common Canister Protocol for Inhaler Administration in Mechanically Ventilated Patients

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Polso SpO2 Accuracy Validation Study

Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only

Substantial Equivalence Study for Kai Sensors RSpot Non-Contact Respiratory Rate Spot Check

FAPI PET for Lung Fibrosis

Afferent Neurocardiac Signals, Cue Reactivity, and Cognitive Control

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Pembrolizumab + Idelalisib for Lung Cancer Study

T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Inspiratory Muscle Strength Training in Adults With Obesity

A Pilot Study of High Intensity Walking in Older Adults in the Pre-operative Period

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Pre-hospital Ventilation Clinical Study

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough

Evaluating Sleep Quality With Emerging Technologies

Placebo In Chronic Back Pain (Phase 2)

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)